• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$22.02 $0.19 (0.87%)

REAL-TIME: Last trade at

Theravance, Inc.

NASDAQ:THRX

GlaxoSmithKline: The Good News Just Keeps On Coming

Theravance to Present at Investor Conferences in June 2012

Theravance to Present at Investor Conferences in June 2012

GlaxoSmithKline completes transaction to increase its ownership in Theravance

Theravance management to meet with Bernstein

Glaxo Hikes Stake in Theravance - Analyst Blog

Glaxo Hikes Stake in Theravance

GSK pays $213 million to raise stake in Theravance to 26.7%

GlaxoSmithKline lifts Theravance stake to 26.7%

GlaxoSmithKline closes on Theravance deal

GlaxoSmithKline boosts Theravance stake

GlaxoSmithKline Completes Transaction to Increase Its Ownership in Theravance

Theravance to Webcast 2012 Annual Meeting of Stockholders on May 15, 2012

Revenues Rise at Theravance - Analyst Blog

Revenues Rise at Theravance - Analyst Blog

Revenues Rise at Theravance

Theravance, Inc. (THRX) Tops Q1 EPS by 9c

Theravance reports Q1 EPS 93c, consensus 84c

Theravance Reports First Quarter 2012 Financial Results

Theravance to Present at Investor Conferences in May 2012

Theravance to Report First Quarter 2012 Financial Results on April 26, 2012

Theravance to Report First Quarter 2012 Financial Results on April 26, 2012

Over Ninety Percent of Surveyed Physicians Will Prescribe GlaxoSmithKline/Theravance’s Relovair If It is on a Preferred Tier While Only about One-Third Will Do So If It is on a Nonpreferred Tier

Over Ninety Percent of Surveyed Physicians Will Prescribe GlaxoSmithKline/Theravance’s Relovair If It is on a Preferred Tier While Only about One-Third Will Do So If It is on a Nonpreferred Tier

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Glaxo to Hike Stake in Theravance

Glaxo to Hike Stake in Theravance - Analyst Blog

GlaxoSmithKline Boosts Stake in Theravance

Notable 52-Week Highs and Lows of the Day 04/02: (TWER) (TXT) (GSK) High; (KERX) (AEZS) (YPF) Low

GlaxoSmithKline to buy 8 percent more of Theravance for $213 million

Boingo Wireless, Roundy’s, Theravance: U.S. Equity Movers

Theravance rises 18%

Notable Mergers and Acquisitions of the Day 04/02: (AVP) (GSK)/(THRX) (DELL) (WWIN)

Theravance has a long range day to the upside, resistance at $24.27 pivot high

GSK and Theravance announce encouraging results from Phase III COPD studies

GlaxoSmithKline to Increase Its Ownership in Theravance

A Look At Seth Klarman's Top Holdings: 5 Value Opportunities For Now

Mixed Data for Glaxo & THRX Drug - Analyst Blog

Mixed Data for Glaxo & THRX Drug - Analyst Blog

Mixed Data for Glaxo & THRX Drug

See More Articles...